O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+33.33%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$6.38B
AUM Growth
+$6.38B
(+19%)
Cap. Flow
-$261M
Cap. Flow
% of AUM
-4.1%
Top 10 Holdings %
Top 10 Hldgs %
40.48%
Holding
147
New
18
Increased
25
Reduced
26
Closed
25
Top Buys
| 1 |
Alector
ALEC
|
$247M |
| 2 |
Neurocrine Biosciences
NBIX
|
$118M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$64M |
| 4 |
AVDR
Avedro, Inc Common Stock
AVDR
|
$52M |
| 5 |
ENDP
Endo International plc
ENDP
|
$49.5M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$279M |
| 2 |
Biogen
BIIB
|
$177M |
| 3 |
AGN
Allergan plc
AGN
|
$128M |
| 4 |
CVS Health
CVS
|
$52M |
| 5 |
Centene
CNC
|
$48.1M |
Sector Composition
| 1 | Healthcare | 96.73% |
| 2 | Financials | 1.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Apellis Pharmaceuticals
APLS
$3.51B
| $34.4M | 0.53% |
1,762,300
+1,435,300
| +439% | +$28M |
|
|
OBSV
52
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $33.3M | 0.52% |
2,605,531
| – | – |
|
53
Adicet Bio
ACET
$60.8M
| $32.9M | 0.51% |
4,830,387
| – | – |
|
54
Prothena Corp
PRTA
$452M
| $29.5M | 0.46% |
+2,435,278
| New | +$29.5M |
|
|
GNFT
55
Genfit
GNFT
$198M
| $29.5M | 0.46% |
+1,230,314
| New | +$29.5M |
|
56
Gilead Sciences
GILD
$140B
| $28.9M | 0.45% |
443,800
| – | – |
|
57
KALA BIO
KALA
$105M
| $28.5M | 0.44% |
3,447,840
| – | – |
|
58
Xtant Medical Holdings
XTNT
$82.4M
| $28.1M | 0.43% |
9,207,012
| – | – |
|
|
CELG
59
DELISTED
Celgene Corp
CELG
| $27.8M | 0.43% |
295,000
-2,961,700
| -91% | -$279M |
|
60
ProQR Therapeutics
PRQR
$256M
| $27.5M | 0.43% |
1,982,031
+544,300
| +38% | +$7.55M |
|
61
Heron Therapeutics
HRTX
$204M
| $26.1M | 0.4% |
1,069,000
-331,300
| -24% | -$8.1M |
|
62
CareDx
CDNA
$678M
| $26.1M | 0.4% |
+827,600
| New | +$26.1M |
|
|
ALPN
63
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $25.2M | 0.39% |
3,670,955
+372,439
| +11% | +$2.55M |
|
|
CBAY
64
DELISTED
Cymabay Therapeutics
CBAY
| $24.9M | 0.39% |
+1,874,955
| New | +$24.9M |
|
65
Corvus Pharmaceuticals
CRVS
$419M
| $24M | 0.37% |
5,967,584
| – | – |
|
66
Amgen
AMGN
$153B
| $23.2M | 0.36% |
122,100
| – | – |
|
|
HARP
67
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $23.2M | 0.36% |
+2,446,409
| New | +$23.2M |
|
68
Enanta Pharmaceuticals
ENTA
$189M
| $22.3M | 0.34% |
+233,100
| New | +$22.3M |
|
69
Natera
NTRA
$23B
| $22.2M | 0.34% |
1,077,586
+393,500
| +58% | +$8.11M |
|
70
Rhythm Pharmaceuticals
RYTM
$6.75B
| $21.6M | 0.33% |
787,300
-141,200
| -15% | -$3.87M |
|
|
71
Biogen
BIIB
$20.8B
| $20.7M | 0.32% |
87,700
-747,549
| -90% | -$177M |
|
72
Aurinia Pharmaceuticals
AUPH
$1.58B
| $20.5M | 0.32% |
+3,149,810
| New | +$20.5M |
|
73
Assembly Biosciences
ASMB
$183M
| $19.6M | 0.3% |
996,123
| – | – |
|
|
FOMX
74
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $19.5M | 0.3% |
5,195,330
| – | – |
|
75
SI-BONE Inc
SIBN
$700M
| $18.6M | 0.29% |
985,368
| – | – |
|